Research programme: antiviral agents - Sirona Biochem
Latest Information Update: 28 Apr 2024
At a glance
- Originator Institute for Antiviral Research; Sirona Biochem
- Developer Sirona Biochem
- Class Antivirals; Carbohydrates; Glycoamines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for research development in COVID-2019-infections in Canada
- 10 Nov 2022 Sirona Biochem enters in collaboration with International Centre for Genetic and Engineering Biotechnology for advancements of antivirals in COVID-2019 infections
- 20 Dec 2021 Sirona Biochem in collaboration with Utah State University's Institute of Antiviral Research plans preclinical trials for COVID-2019 infections in USA